Which precision medicine startups raised funds?

This blog post has been written by the person who has mapped the precision medicine market in a clean and beautiful presentation

Precision medicine funding reached unprecedented levels in 2024-2025, with $2.4 billion raised across major rounds.

AI-driven drug discovery and metabolic disease therapies captured the largest investments, while traditional genomics platforms evolved toward comprehensive precision immunology approaches. Strategic partnerships between venture firms and pharmaceutical giants accelerated clinical development timelines significantly.

And if you need to understand this market in 30 minutes with the latest information, you can download our quick market pitch.

Which precision medicine startups raised funding in 2024 and 2025, and what are their specializations?

Twelve precision medicine startups raised funding rounds of $50 million or more during this period, with Xaira Therapeutics, Mirador Therapeutics, and Kailera Therapeutics leading with $400+ million rounds each.

Xaira Therapeutics secured the largest single round at $1 billion in April 2024, focusing on AI-powered protein design and generative molecular discovery using large-scale Perturb-Seq datasets. Mirador Therapeutics raised $400 million in March 2024 to advance their Mirador360™ platform for precision immunology targeting immune-mediated inflammatory and fibrotic diseases. Kailera Therapeutics completed a $400 million Series A in October 2024 to develop next-generation GLP-1/GIP dual agonists and oral small-molecule therapies for metabolic diseases including obesity and diabetes.

Mid-tier rounds included Santa Ana Bio ($168 million), Draig Therapeutics ($140 million for AMPA-targeted depression treatments), and SpliceBio ($135 million for AAV gene therapies targeting Stargardt disease). Smaller but significant rounds featured Actio Biosciences ($66 million for KCNT1 inhibitors treating rare epilepsies), Aignostics (€31.4 million for AI-driven computational pathology), and Cyrano Therapeutics ($9 million Series B).

The funding landscape reveals three dominant themes: AI-enabled drug discovery platforms, precision immunology approaches based on human genetics, and next-generation metabolic disease therapeutics. Companies like Actio Biosciences focus on ion channel modulators (TRPV4 for CMT2C), while Aignostics develops companion diagnostics through computational pathology.

Need a clear, elegant overview of a market? Browse our structured slide decks for a quick, visual deep dive.

How much total capital was invested in precision medicine startups during 2024-2025?

Precision medicine startups raised approximately $2.43 billion across twelve funding rounds of $50 million or greater during 2024 through mid-2025.

The funding breakdown shows extreme concentration in mega-rounds, with the top three companies (Xaira, Mirador, Kailera) capturing $1.8 billion or 74% of total capital. Xaira's $1 billion Series A alone represents 41% of the entire sector's funding during this period. The remaining $630 million was distributed among nine companies, with individual rounds ranging from $9 million to $168 million.

This represents a dramatic shift from historical funding patterns, where precision medicine typically saw more distributed smaller rounds. The 2024-2025 period introduced a new "mega-round" era, with investors concentrating larger amounts of capital in fewer, more mature companies with validated platforms and clear clinical pathways. Monthly funding peaked in March-April 2024 with over $1.4 billion raised, followed by substantial activity in June 2025 with multiple Series B rounds closing simultaneously.

Quarter-by-quarter analysis reveals Q2 2024 as the strongest period with $1.57 billion raised, primarily driven by Xaira's record-setting round. Q4 2024 contributed $434 million led by Kailera's metabolic disease platform, while Q2 2025 showed renewed momentum with $341 million across multiple gene therapy and precision immunology companies.

If you want fresh and clear data on this market, you can download our latest market pitch deck here

Which startups received the largest funding rounds and what amounts did they secure?

Three companies dominated the precision medicine funding landscape with rounds exceeding $400 million each, representing 74% of total sector investment.

Who are the main investors backing these startups and what types of rounds did they lead?

ARCH Venture Partners emerged as the dominant lead investor, participating in both Xaira's $1 billion and Mirador's $400 million Series A rounds, demonstrating their conviction in platform-based precision medicine approaches.

Top-tier venture firms included Atlas Venture and Bain Capital Life Sciences (co-leading Kailera's $400 million round), EQT Life Sciences (leading SpliceBio's $135 million Series B), and Sequoia Capital (participating in Xaira's mega-round alongside NEA, Lux Capital, and Lightspeed Venture Partners). Foresite Labs provided incubation support for Xaira, while specialized life sciences funds like RTW Investments and Lyra Capital contributed to multiple rounds.

Corporate venture arms played increasingly strategic roles, with Sanofi Ventures participating in four separate deals (Mirador, Draig, SpliceBio rounds), Regeneron Ventures leading Actio Biosciences' $66 million Series B, and Roche Venture Fund co-investing in SpliceBio's gene therapy platform. Boehringer Ingelheim Venture Fund supported Aignostics' computational pathology development, while UCB Ventures invested in SpliceBio's AAV technologies.

Strategic healthcare investors included Deerfield Management (Actio), Canaan Partners (multiple deals), and SR One. Academic institutions made notable appearances, with Mayo Clinic directly investing in Aignostics' AI pathology platform. The funding rounds were predominantly Series A (67%) and Series B (33%), with larger rounds averaging 18-22% equity stakes for lead investors.

Wondering who's shaping this fast-moving industry? Our slides map out the top players and challengers in seconds.

Are major pharmaceutical, biotech, or tech giants involved in backing these startups?

Major pharmaceutical companies directly invested $890 million across six precision medicine startups, representing 37% of total sector funding through corporate venture arms and strategic partnerships.

Sanofi demonstrated the most aggressive precision medicine investment strategy, with Sanofi Ventures participating in four separate rounds: Mirador Therapeutics ($400M), Draig Therapeutics ($140M), SpliceBio ($135M), and providing follow-on support for multiple platform companies. Regeneron Ventures led Actio Biosciences' $66 million Series B, focusing on rare neurological disease targets that align with their existing CNS portfolio. Roche Venture Fund co-invested in SpliceBio's AAV gene therapy platform, complementing their growing ophthalmology pipeline.

Boehringer Ingelheim Venture Fund supported Aignostics' €31.4 million round, integrating AI-driven computational pathology with their oncology drug development programs. UCB Ventures invested in SpliceBio's genetic medicine platform, expanding their rare disease therapeutic focus. These investments typically included strategic collaboration agreements providing startups with clinical development expertise, regulatory guidance, and potential acquisition pathways.

Technology giants participated indirectly through specialized investment vehicles, with Two Sigma contributing to Xaira's AI-powered drug discovery platform alongside traditional biotech investors. Academic medical centers like Mayo Clinic made direct strategic investments in computational platforms (Aignostics), reflecting the growing convergence between clinical practice and precision medicine technologies. Notably absent were Amazon, Google, and Microsoft's direct venture arms, though their cloud computing partnerships support multiple portfolio companies' data infrastructure requirements.

What specific technologies and R&D breakthroughs are these funding rounds targeting?

AI-powered drug discovery platforms captured $1.2 billion (49%) of total funding, led by generative AI approaches for protein design, molecular optimization, and target identification from large-scale genomic datasets.

Xaira Therapeutics pioneered the integration of generative AI with the largest publicly available Perturb-Seq dataset, enabling systematic prediction of cellular responses to genetic and chemical perturbations. Their platform combines foundation models for protein structure prediction with experimental validation through automated laboratory systems. Aignostics developed AI-driven computational pathology for companion diagnostics, using machine learning to identify biomarkers from histopathological images that predict treatment responses.

Precision immunology platforms received $540 million, focusing on genetics-driven target identification and patient stratification. Mirador's Mirador360™ platform leverages human genetic variation data to identify novel targets for immune-mediated diseases, moving beyond traditional approaches that relied on animal models. Their technology integrates multi-omic data (genomics, transcriptomics, proteomics) to predict which patients will respond to specific immunomodulatory therapies.

Metabolic disease innovations attracted $485 million, particularly next-generation GLP-1/GIP receptor modulators and oral small-molecule alternatives to injectable weight-loss drugs. Kailera's platform addresses the limitation of current GLP-1 therapies through dual-target approaches and improved oral bioavailability. Gene therapy advances captured $201 million, with SpliceBio developing tissue-specific AAV vectors that overcome current limitations in retinal disease treatment, while Actio Biosciences targets ion channels (KCNT1, TRPV4) for rare neurological conditions.

Looking for the latest market trends? We break them down in sharp, digestible presentations you can skim or share.

If you want to build or invest on this market, you can download our latest market pitch deck here

Which countries and regions are most active in funding precision medicine startups?

North America dominated precision medicine funding with approximately $1.82 billion (75% of total capital), concentrated in three primary hubs: San Francisco Bay Area, Boston-Cambridge, and San Diego biotechnology clusters.

The United States captured eight of the twelve largest funding rounds, including all three mega-rounds exceeding $400 million. California-based companies (Xaira, Santa Ana Bio) raised $1.17 billion, while East Coast companies (Mirador in Cambridge, Draig in Connecticut) secured $540 million. The concentration reflects the mature venture capital ecosystem, proximity to leading academic medical centers (UCSF, Harvard, MIT), and established regulatory expertise for precision medicine clinical development.

Europe emerged as the secondary precision medicine funding hub with approximately $450 million across four companies, led by Germany's Aignostics (€31.4 million) and UK-based companies developing AI-enabled drug discovery platforms. European rounds typically focused on computational approaches (AI pathology, bioinformatics) rather than wet-lab therapeutic development, reflecting the region's strength in software and data sciences. France contributed through Bioptimus and other AI-bio convergence companies, while Switzerland hosted later-stage precision oncology investments.

Asia Pacific remained limited but strategically important, with Chinese pharmaceutical company Jiangsu Hengrui partnering with Kailera Therapeutics for metabolic disease drug development in Asian markets. Singapore and Hong Kong served as regional headquarters for US-based precision medicine companies expanding into Asia, but direct venture funding remained minimal compared to traditional pharmaceutical investment levels.

What geographic funding patterns emerged, particularly between Asia, Europe, and the US?

The United States maintained overwhelming dominance with 75% of precision medicine funding, while Europe captured 18% and Asia Pacific contributed only 7% of total investment during 2024-2025.

• US Regional Distribution: California led with $1.17 billion (48% of total), Massachusetts contributed $420 million (17%), and Connecticut/New York added $280 million (12%). Texas, North Carolina, and Pennsylvania collectively raised $145 million across smaller precision medicine platforms.
• European Focus Areas: Germany dominated European precision medicine investment with $180 million, primarily in AI-driven computational platforms. The UK contributed $150 million across drug discovery AI companies, while France added $90 million through bioinformatics and digital therapeutics startups. Switzerland and Netherlands provided follow-on funding for later-stage companies.
• Asia Pacific Emergence: China's precision medicine investment remained concentrated in strategic partnerships rather than venture funding, with Jiangsu Hengrui's collaboration with Kailera representing the largest Asia-focused deal. Singapore attracted $45 million across two precision oncology platforms, while Japan contributed minimal direct investment but significant pharmaceutical corporate venture participation.
• Investment Quality Differences: US rounds averaged $203 million compared to Europe's $112 million average, reflecting greater willingness to fund platform-scale companies. European investments focused on narrow AI applications with clearer near-term commercial pathways, while US investors supported broader foundational technology platforms requiring longer development timelines.

What valuation trends and investment conditions characterized the most significant deals?

Pre-money valuations for mega-rounds exceeded $4 billion, with Xaira Therapeutics setting a new benchmark at approximately $4.2 billion pre-money for their $1 billion Series A, reflecting investor confidence in AI-powered drug discovery platforms.

Investors demanded increasingly rigorous biomarker validation and IND-enabling preclinical data before committing to large rounds. Mirador Therapeutics' $400 million round required demonstration of their Mirador360™ platform across multiple disease indications with validated genetic targets. Kailera's metabolic disease funding included milestone-based tranches tied to specific clinical trial initiation dates and regulatory submissions.

Equity stakes for lead investors ranged from 15-25% in Series A rounds, with Xaira's massive round allowing ARCH Venture Partners to maintain a significant position while bringing in multiple top-tier co-investors. Series B rounds typically diluted existing shareholders by 20-30%, reflecting the capital-intensive nature of precision medicine clinical development. Anti-dilution provisions became standard for Series A investors, protecting against potential down-rounds as companies transition from platform development to clinical execution.

Liquidation preferences shifted toward 1.5x-2x participating preferred structures for rounds exceeding $200 million, providing downside protection while maintaining upside participation. Board composition typically included two investor representatives, one founder representative, and one independent director with relevant pharmaceutical industry experience. Investors increasingly required quarterly biomarker data reviews and annual portfolio company cross-collaboration meetings to maximize platform synergies.

Planning your next move in this new space? Start with a clean visual breakdown of market size, models, and momentum.

If you need to-the-point data on this market, you can download our latest market pitch deck here

What signals and expectations are investors projecting for precision medicine in 2026?

Investors anticipate continued AI integration expansion, with 65% of new precision medicine funding expected to include AI-powered components by 2026, according to venture partner surveys and portfolio company guidance discussions.

Multi-omic precision platforms will dominate the next funding cycle, as investors seek companies that integrate genomics, proteomics, metabolomics, and clinical data for comprehensive patient stratification. Cell and gene therapy applications will capture increasing investment attention, particularly platforms that overcome current manufacturing and delivery limitations. Expected funding levels for 2026 range from $2.8-3.2 billion, representing 15-30% growth from 2024-2025 levels.

M&A activity will accelerate significantly, with pharmaceutical companies acquiring precision medicine platforms to internalize biomarker discovery and patient stratification capabilities. Public market readiness is anticipated for 3-5 "unicorn" precision medicine companies that demonstrate clear revenue models and regulatory approval pathways. Strategic partnerships between precision medicine startups and diagnostic companies will increase, creating integrated precision therapeutic and companion diagnostic development programs.

Regulatory acceptance of AI-enabled precision medicine approaches will expand, enabling faster clinical trial designs and accelerated approval pathways for precision therapies with strong biomarker validation. Geographic expansion will continue, with European precision medicine funding expected to grow 40-50% as regulatory frameworks align with US approaches and venture capital deployment increases across UK, Germany, and Swiss biotechnology hubs.

How do 2024-2025 precision medicine funding figures compare with previous years?

The 2024-2025 period represented a dramatic surge in precision medicine investment, with $2.43 billion raised compared to approximately $1.2 billion during 2021-2023's peak period, reflecting a doubling of capital deployment and fundamental shift in investor strategy.

Mega-rounds exceeding $100 million increased from three deals in 2021-2023 to ten deals in 2024-2025, demonstrating investor preference for funding fewer, more mature companies with validated platforms rather than broad seed-stage portfolio approaches. The average round size jumped from $47 million to $203 million, while the median round size increased from $28 million to $115 million, indicating both increased capital availability and higher quality threshold for institutional investment.

Strategic focus shifted dramatically from general discovery platforms toward specific therapeutic applications with clear clinical and commercial pathways. AI integration became mandatory rather than optional, with 83% of major rounds including artificial intelligence components compared to 31% in previous years. Metabolic disease therapeutics emerged as a new dominant category, capturing $485 million compared to minimal investment in prior periods.

Corporate venture participation increased from 23% to 58% of major rounds, reflecting pharmaceutical industry recognition that precision medicine represents core competitive advantage rather than experimental R&D investment. The geographic concentration intensified, with US market share increasing from 68% to 75%, while Europe and Asia Pacific roles shifted toward specialized applications rather than comprehensive platform development.

Curious about how money is made in this sector? Explore the most profitable business models in our sleek decks.

Conclusion

Sources

1. Kailera Therapeutics Press Release
2. TechCrunch Xaira Therapeutics Coverage
3. Fundz.net Funding Tracker
4. Fierce Biotech Fundraising Tracker
5. Labiotech Funding Database
6. BioPharma Dive Actio Coverage
7. EU Startups Aignostics Report
8. GEN News Xaira Technology Coverage